Literature DB >> 14761804

Magnetic resonance imaging in drug discovery: lessons from disease areas.

Nicolau Beckmann1, Didier Laurent, Bruno Tigani, Rogério Panizzutti, Markus Rudin.   

Abstract

Imaging technologies are presently receiving considerable attention in the pharmaceutical area owing to their potential to accelerate the drug discovery and development process. One of the principal imaging modalities is magnetic resonance imaging (MRI). The multiparametric nature of MRI enables anatomical, functional and even molecular information to be obtained non-invasively from intact organisms at high spatial resolution, thereby enabling a comprehensive characterization of a disease state and the corresponding drug intervention. The non-invasiveness of MRI strengthens the link between pre-clinical and clinical drug studies, making the technique attractive for pharmaceutical research.

Mesh:

Year:  2004        PMID: 14761804     DOI: 10.1016/S1359-6446(04)02943-5

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  2 in total

1.  Brain T1 intensity changes after levodopa administration in healthy subjects: a voxel-based morphometry study.

Authors:  Pilar Salgado-Pineda; Pauline Delaveau; Carles Falcon; Olivier Blin
Journal:  Br J Clin Pharmacol       Date:  2006-06-23       Impact factor: 4.335

2.  Desorption electrospray ionization mass spectrometry: Imaging drugs and metabolites in tissues.

Authors:  Justin M Wiseman; Demian R Ifa; Yongxin Zhu; Candice B Kissinger; Nicholas E Manicke; Peter T Kissinger; R Graham Cooks
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-12       Impact factor: 11.205

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.